Baxalta Announces Opening of Global Innovation Center
News Dec 15, 2015
Baxalta Incorporated has announced the official opening of its Global Innovation Center in Cambridge, Massachusetts. The Center is located in Kendall Square at 650 East Kendall Street and will act as the innovation hub of the company’s global infrastructure designed to effectively deliver advanced treatments to patients.
“We are honored to join this robust biotech community in Cambridge,” said John Orloff, M.D., head of Research & Development and chief scientific officer, Baxalta. “Kendall Square was a natural choice for the location of our Global Innovation Center. Here we are surrounded by some of the top minds in the industry, immersed in a biotech community that is unparalleled by any other in the world. Our goal is to become a leading development powerhouse to deliver innovative treatments for patients with unmet medical needs.”
Baxalta’s innovation efforts are focused on the development of lifesaving therapies in hematology, immunology and oncology. The company’s approach to expanding its pipeline is based on an external innovation model, sourcing compounds externally through in-licensing or acquisitions.
The Cambridge life science community will provide Baxalta access to a range of innovations and collaboration partners with complementary expertise to advance new treatments for patients.
Baxalta has approximately 40 programs in development, and plans to launch 20 new products by 2020, leveraging its experienced leadership team, existing global capabilities and footprint in more than 100 countries.
“Massachusetts is home to an extensive community of top-tier academic institutions, research facilities and life-science companies,” said Governor Charlie Baker. “The biotechnology cluster is an important part of our life-science community and a key driver for our economy. We remain committed to the life-sciences and welcome Baxalta to the Commonwealth.”
The Center supports cross-functional, co-located teams including R&D, Oncology, Biosimilars, Business Development, Corporate Strategy and Customer Operations, along with others that support or work closely with R&D.
By the end of 2015, Baxalta expects to employ approximately 500 individuals at the Global Innovation Center. In addition, the company also operates a hemophilia treatment manufacturing facility in Milford, Massachusetts.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE